FDA
-
-
-
-
-
-
-
KeyBanc Upgrades CryoPort (CYRX) to Overweight
-
-
-
-
-
-
-
Cryoport Reports Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Cryoport Reports Results for the Third Quarter 2022
-
-
-
-
-
-
-
After-Hours Stock Movers 01/19: (NFLX) (CKPT) (PCAR) Higher; (HSTO) (BLRX) (ACRX) Lower (more...)
-
-
-
-
-
-
-
Cryoport Revenue Grows 76% for Third Quarter 2018; 91% Growth in Biopharma
-
-
-
-
-
-
-
Roth Capital Starts CryoPort (CYRX) at Buy
-
-
-
-
-
-
-
Cryoport (CYRX): FDA Unanimously Approves Experimental CAR-T Therapy - Needham
-
322,969 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

